Stocks · News reference
HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-14 AccNo: 0001193125-26-352403 Size: 231 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share